Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF

Serum amylin level in Behçet’s disease and relation to parameters of metabolic syndrome and disease activity

Egyptian Rheumatology and Rehabilitation volume 45, pages 112–116 (2018)Cite this article

Abstract

Background

Insulin resistance is found in Behçet’s disease and associated with the development of metabolic syndrome. Our study explored whether amylin, which is involved in insulin resistance and development of metabolic syndrome, is observed in patients with Behçet’s disease.

Aim

Our aim was to assess serum levels of amylin in patients with Behçet’s disease and evaluate its relation to metabolic syndrome.

Patients and methods

Thirty Behçet’s disease patients and 30 controls matched by age, sex, and BMI were studied. The disease activity was assessed using the Behçet’s disease Current Activity Form score. Serum amylin level was studied using the enzyme-linked immunosorbent assay method.

Results

Our result showed that 11 (36.6%) patients under study were diagnosed with the metabolic syndrome, and there were significant differences between Behçet’s cases and control groups in cholesterol, triglyceride, and low-density lipoprotein levels (P<0.05). Amylin level was 392.2 μg/dl in Behçet’s cases compared with 659.9 μg/ dl in the control group. The difference was statistically significant at P value less than 0.05. There was a negative correlation between amylin levels and parameters of metabolic syndrome, a significant difference in amylin levels between Behçet’s patients with an active manifestation and patient with an inactive manifestation.

Conclusion

Amylin serum levels were significantly lower in patients with Behçet’s disease, indicating that this hormone could be a factor for the development of metabolic syndrome in Behçet’s disease.

References

  1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735–2752

    Article  Google Scholar 

  2. Alireza K, Mehrzad H, Noei M. Metabolic syndrome in Behcet’s disease. International Conference on Behcet’s Disease; 2014; Emamreza, Tabriz, Iran. pp. 18–20

    Google Scholar 

  3. Ulasoglu C, Mesci B, Karagöz E, Karagöz V, Akın Y, Öztürk H, et al. Frequency of metabolic syndrome and nonalcoholic fatty liver in Behçet’s disease. Nobel Med J 2013; 9:35–42

    Google Scholar 

  4. Higham CE, Hull RL, Lawrie L, Shennan KI, Morris JF, Birch NP, et al. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) amylin by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 2005; 267:4998–5004

    Article  Google Scholar 

  5. Hou X, Sun L, Li Z, Mou H, Yu Z, Li H, et al. Associations of amylin with inflammatory markers and metabolic syndrome in apparently healthy Chinese. PLoS One 2011; 6:e24815

    Article  CAS  Google Scholar 

  6. Davatchi F, Assaad KS, Calamia KT. International Team for the Revision of the International Criteria for Behcet’s Disease: a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28:338–347

    Article  Google Scholar 

  7. Forbess C, Swearingen C, Yazici Y. Behçet’s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Behçet’s Disease Current Activity Form (BDCAF). Arthritis Rheum 2008; 58(Suppl):S854

    Google Scholar 

  8. Beilby J. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Clin Biochem Rev 2004; 25: 195–198

    PubMed Central  Google Scholar 

  9. Lutz TA, Meyer U. Amylin at the interface between metabolic and neurodegenerative disorders. Front Neurosci 2015; 9:216

    Article  Google Scholar 

  10. Abou-Raya A, Abou-Raya S, Helmii M. Metabolic syndrome in Behçet’s disease: association with disease activity and systemic inflammation. Ann Rheum Dis 2014; 73:993

    Article  Google Scholar 

  11. Yalç NB, Gür G, Artüz F, All N. Prevalence of metabolic syndrome in Behçet disease : a case-control study in Turkey. Am J Clin Dermatol 2013; 14: 421–425

    Article  Google Scholar 

  12. Sadrbafoghi SM, Salari M, Rafiee M, Namayandeh SM, Abdoli AM, Karimi M, et al. Prevalence and criteria of metabolic syndrome in an urban population: Yazd Healthy Heart Project. Tehran Univ Med J 2006; 64: 90–96

    Google Scholar 

  13. Azizi F, Etemadi A, Salehi P, Zahedi Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Tehran Univ Med J 2003; 61:389–399

    Google Scholar 

  14. Dogan FB, Cicek D, Aydin S, Dertlioglu SB, Halisdemir N, Ucak H, et al. Serum preptin and amylin values in psoriasis vulgaris and Behcet’s patients. J Clin Lab Anal 2016; 30:165–168

    Article  CAS  Google Scholar 

  15. Rafacho A, Ortsäter H, Nadal A, Quesada I. Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J Endocrinol 2014; 223: R49–R62

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Rehabilitation, Zagazig University, Zagazig, Egypt

    Shimaa M. Abdelwhab (Lecturer) & Omima Z. Shehata

  2. Department of Biochemistry, Zagazig University, Zagazig, Egypt

    Yousry A. El Magd & Amal Kamal

Authors
  1. Shimaa M. Abdelwhab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omima Z. Shehata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yousry A. El Magd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amal Kamal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shimaa M. Abdelwhab.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdelwhab, S.M., Shehata, O.Z., El Magd, Y.A. et al. Serum amylin level in Behçet’s disease and relation to parameters of metabolic syndrome and disease activity. Egypt Rheumatol Rehabil 45, 112–116 (2018). https://doi.org/10.4103/err.err_42_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/err.err_42_17

Keywords